SCHEMBL15907233

SCHEMBL15907233

C#Cc1cc(NC(=O)c2ccc(C(N)=O)cc2)nnc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
TP53 P04637 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
PLAU P00749 1/20 0.39
PARP10 Q53GL7 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
PARP1 P09874 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
PARP4 Q9UKK3 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907185 0.81 BCAT2 (0.43) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL18323192 0.76 RAB9A (0.33) KMT2ANPC1RAB9ATP53SMN1; SMN2
SCHEMBL15907231 0.74 MAP3K5 (0.42) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL15907296 0.73 CHEK1 (0.36) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL15907230 0.71 MAPT (0.38) POLBTP53SMN1; SMN2MAPT
SCHEMBL15907209 0.68 NPC1 (0.50) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL15308166 0.67 NPC1 (0.59) MEN1KMT2APOLBCCNA2CDK2
SCHEMBL15907178 0.65 BCAT2 (0.54) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18323173 0.65 NPC1 (0.49) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL18323168 0.62 BCAT2 (0.54) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 MEN1 1500/4885KMT2A 1272/4885POLB 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.